Blood biomarkers have made earlier biological detection of Alzheimer's disease possible. But are patients truly benefiting?
Scientific discovery alone does not change patient outcomes. Implementation does.
The next chapter in Alzheimer's care is no longer about whether p-tau217 works. It is about building the ecosystem that translates innovation into impact.
That requires:
Physician confidence and education
Evidence-based clinical guidelines
Regulatory approval and standardized laboratory implementation
Reimbursement supported by real-world evidence
Effective disease-modifying therapies
Integrated primary care pathways
The science is advancing rapidly. Blood biomarkers can reduce unnecessary PET scans and lumbar punctures, identify patients who may benefit from therapy, and simplify the diagnostic journey.
Yet one critical question remains:
Can we successfully implement these advances at scale to measurably improve patient outcomes?
Implementation science is the bridge between discovery and impact. As two FDA-approved disease-modifying therapies become available and the pipeline continues to grow, ensuring patients benefit will depend not only on the biomarker—but on our ability to integrate diagnostics, evidence generation, reimbursement, and clinical care into a coordinated precision medicine ecosystem.
The science is no longer the bottleneck. Healthcare system readiness is.
References:
Phares S, Kremer I, Wall JK, Wood J, Baumgart M, Dickson S, Fickie M, Hubbard T, Jannati A, Monane M, Rivet C, Hirsch G. System changes to empower primary care in Alzheimer's disease detection and care. Alzheimers Dement. 2026 Apr;22(4):e71276. doi: 10.1002/alz.71276. PMID: 42047299; PMCID: PMC13122564.
Burns JM, Morris JK, Vidoni ED, Townley RA, Gillen LR, Smith TR, Jones JE, Nelson MB, Mudaranthakam DP, Perales-Puchalt J, Lewandowski T, Niedens CM, Parks AC, Brunette AM, Aschenbrenner AJ, Bucy TI, Forcino RC, Woodward JL. Brain health care accelerator: A primary care-centered model for scaling dementia diagnosis and care. Alzheimers Dement. 2026 Apr;22(4):e71405. doi: 10.1002/alz.71405. PMID: 41988865; PMCID: PMC13084531.
Atri A, Dickerson BC, Clevenger C, Karlawish J, Knopman D, Lin PJ, Norman M, Onyike C, Sano M, Scanland S, Carrillo M. Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for primary care. Alzheimers Dement. 2025 Jun;21(6):e14333. doi: 10.1002/alz.14333. Epub 2024 Dec 23. PMID: 39713942; PMCID: PMC12173843.
Comments